Skip to main content
. 2010 Mar 25;16(1):71–76. doi: 10.1177/159101991001600109

Figure 4.

Figure 4

Contrast-enhanced T1-weighted MRI of the brain before (A,B) and 24 hours after (C,D) superselective intra-arterial cerebral infusion of bevacizumab demonstrating a significant decrease in enhancement within the targeted region of treatment.